NON-INVASIVE CANCER SOLUTIONS
Safe | Accurate | Easy on the Patient

YOUR ARMAMENTARIUM AGAINST CANCER

Trublood

The No Risk Biopsy

Fast, risk free diagnosis without any invasive procedure for patients advised an invasive biopsy.

Celldx Deep Genomic Analysis of Tumor Tissue

Ultra-fast, in depth tumour profiling of tumour tissue at reasonable charge.

Exacta

Encyclopedic Tumor Analysis

Speedy, meticulous Personalised Treatment Plan created by experts using a method that is clinically proven.

Chemo-Scale Efficacy and Resistance Guidance for Chemotherapy

Non-Invasive in vitro Chemosensitivity on C-TACs to evaluate Response / Resistance to chemotherapy drugs.

Trublood

The No Risk Biopsy

Celldx

Deep Genomic Analysis of Tumor Tissue

Exacta

Encyclopedic Tumor Analysis

Chemo-Scale

Efficacy and Resistance Guidance for Chemotherapy.

CONTACT US

GET IN TOUCH WITH US

24 x 7 Online Response : response@datarpgx.com

English_Address

FOLLOW US

FOLLOW US



Direct Benefit to Patient	Speedy, meticulous Personalised Treatment Plan created by experts using a method that is clinically proven.
What	Encyclopedic Tumor Analysis of live tumor cells obtained either from freshly biopsied tumor tissue or Circulating biomarkers harvested from peripheral blood.
For Whom	Patients with drug resistant cancers who have failed one or more line of treatment. Patients who have a difficult cancer.
Why	Drug resistant cancers are difficult to treat and need to be managed with multi-dimensional investigations or the tumor characteristics.
How	DNA, RNA, Immunohistochemistry and live cells chemosensitivity data are analysed and integrated to come up with a treatment plan individualised for the patient’s cancer.
Sample Type	Freshly biopsied tumor tissue / 22 ml peripheral blood (5-6 hours fasting) as per protocol.
Turn Around Time	10-12 days



What	Non-Invasive in vitro Chemosensitivity on Circulating Tumor Associated Cells (C-TACs) to evaluate Resistance to chemotherapy drugs already administered.
For Whom	All patients who have received chemotherapy at any stage of the disease.
Why	Cancer cells have innate resistance to chemotherapy drugs and patients may not derive any benefit from therapy initiation itself. Also, such cells acquire resistance over a period of time although initially the cancer responds to treatment. It is necessary to be mindful of drug resistance so that patients do not suffer the cost and toxicity of useless drugs.
How	C-TACs from peripheral blood are isolated and tested in vitro to observe comparative cell death when exposed to calibrated doses of cytotoxic drug which is required to be monitored for resistance.
Sample Type	22 ml peripheral blood (5-6 hours fasting) as per protocol.
Turn Around Time	8-10 days



What	Non-Invasive in vitro Chemosensitivity on Circulating Tumor Associated Cells (C-TACs) to evaluate Response / Resistance to chemotherapy drugs.
For Whom	All patients who have been advised chemotherapy at any stage of the disease.
Why	The choice of chemotherapy drugs is presently based on statistical probability of efficacy. However, a large number of patients fail on such treatments due to non-specific selection of drugs. Chemo-scale identifies the drugs which have highest probability of response and highest risk of resistance to eliminate trial and error on the patient.
How	C-TACs from peripheral blood are isolated and tested in vitro to observe comparative cell death when exposed to calibrated doses of cytotoxic drugs.
Sample Type	22 ml peripheral blood (5-6 hours fasting) as per protocol.
Turn Around Time	8-10 days



Direct Benefit to Patient	Fast, risk free diagnosis without any invasive procedure for patients advised an invasive biopsy.
What	Non-Invasive Diagnostic biopsy to substitute invasive tissue extraction.
For Whom	Symptomatic individuals who have been advised a biopsy to check for malignancy. Patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations. Suspected metastatic relapse to rule out new primary.
Why	Invasive biopsies are risky, inconvenient, painful and must be performed in a clinical setting. Trublood sample can be collected from patient’s home or office.
How	Circulating Tumor Cells and Nucleic Acid are isolated from the patient’s blood samples and extensively analysed for diagnosis, prognosis and theranostics.
Sample Type	17 / 25 ml peripheral blood (5-6 hours fasting) as per protocol depending upon extent of test.
Turn Around Time	Report will be available within 8-10 days depending upon test.

Usual Tissue Biopsy / FNAC	Trublood
Invasive, needs tissue and is ultimately expensive	Totally non invasive and is ultimately less expensive
Can be performed only in Hospital / with Anesthesia	No need for Hospitalization / Anesthesia
Usually painful, may need stitches and leave scars	No Pain, No Stitches, No Scars
Serious risk of tumor cell ‘Seeding’	No Risk
Can be very risky for organs like Lung, Liver, Pancreas	No risk of injury to any organ / bleeding
May be misleading as it is site / time dependent	Provides ‘Real time’ data and covers all active sites
Serial / sequential biopsies are impossible	Can be performed as often as necessary
Not viable if primary tumor is not easily visualized	Viable even if primary / metastasis are undetectable



Direct Benefit to Patient	Ultra-fast, in depth tumour profiling of tumour tissue at reasonable charge.
What	Deep Genomic Analysis of tumor tissue.
For Whom	For patients diagnosed with cancer and advised molecular profiling of the tumor to explore targeted therapies / immunotherapies.
Why	Efficacy of targeted therapies / immunotherapies is conditional upon specific molecular aberrations in the tumor.
How	FFPE embedded tumor tissue is analysed by a powerful NGS assay along with immunohistochemistry.
Sample Type	FFPE block with at least 5% tumor content.
Turn Around Time	8-10 days



What	Analysis of Cell Free DNA (cfDNA) and Circulating Tumor Associated Cells (C-TACs) to check treatment response / recurrence.
For Whom	Patients who have been treated and are required to be monitored for response to treatment or for recurrence.
Why	Radiological imaging is not always able to detect changes in the tumor at the molecular level or early signs of recurrence. Additionally, there are inherent risks associated with radiological imaging.
How	cfDNA from the patient’s peripheral blood is analysed for qualitative and quantitative changes in targeted genes.
Sample Type	22 ml peripheral blood (5-6 hours fasting) as per protocol.
Turn Around Time	10-12 days



What	EasyCheck 360™ is a powerful combination of tests which for the first time incorporate noninvasive detection of 16 cancers and other critical blood markers for a 360º evaluation of health of individuals above the age of 35 years.
For Whom	EasyCheck 360™ is recommended for all men and women above the age of 35 years who have no direct symptoms of cancer and who have no personal history of cancer.
Why	Early detection of cancer is critical for successful treatment and cure. Late detection invariably results in poor prognosis, very toxic drugs and high financial costs. The combining of cancer screening and other functional tests ensures ‘One Prick – Annual Screening’ to de-risk against potentially life threatening diseases in good time.
How	EasyCheck 360™ cancer screening is based upon breakthrough technology for detection of Circulating Tumor Cells (CTCs) which are released in the blood by malignant tumors. CTCs are very rare (about 1 to 100 CTCs per 100 – 150 million normal cells in the blood). The technology has been clinically proven through CTRI (government) registered clinical trials with over 40,000 samples from 22,000 healthy individuals and 18,000 cancer patients. The other blood tests (liver, kidney, thyroid etc.) are performed at the Thyrocare Laboratory which is one of the largest and most proficient pathology labs not only in India but worldwide.
OPTIONS	EasyCheck 360™ is available in three options: EasyCheck 360™ to detect up to 16 cancers and costs ₹5,999. Enhanced Package which covers 101 tests including 16 cancers and costs ₹8,999.
Turn Around Time	Report will be made available within 7 days from the time the sample reaches the central laboratory.